Payment overview · 2025
General Payments
$220.33
14 reported records · 7 companies
Healthcare provider profile · identity verified
Travis M Sanger, MD
Allopathic & Osteopathic Physicians|Family Medicine · ARMOUR, SD · NPI 1922054378
Verified facts
What the public records show
CMS Open Payments records show Travis M Sanger, MD received $220.33 in general payments during 2025 across 14 reported records.
Amgen Inc. accounted for 26.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $57.21 | 26.0% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.84 | 22.6% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $48.45 | 22.0% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.94 | 8.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.68 | 7.6% | 1 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $15.57 | 7.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.64 | 6.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $220.33 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $48.45 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $33.75 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $27.96 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $27.96 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 63 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
106 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 341 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 281 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 231 | 36 |
| Furosemide | Furosemide | 211 | 31 |
| Losartan Potassium | Losartan Potassium | 205 | 32 |
| Atorvastatin Calcium | Atorvastatin Calcium | 185 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 182 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 175 | 31 |
| Simvastatin | Simvastatin | 164 | 33 |
| Lisinopril | Lisinopril | 161 | 30 |
| Gabapentin | Gabapentin | 145 | 18 |
| Meloxicam | Meloxicam | 110 | 19 |
| Metformin Hcl | Metformin Hcl | 110 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 109 | 24 |
| Eliquis | Apixaban | 106 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 101 | 29 |
| Potassium Chloride | Potassium Chloride | 93 | 17 |
| Prednisone | Prednisone | 83 | 48 |
| Baclofen | Baclofen | 77 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 76 | 17 |
| Donepezil Hcl | Donepezil Hcl | 73 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 69 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 68 | 13 |
| Jardiance | Empagliflozin | 63 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 62 | 16 |
| Montelukast Sodium | Montelukast Sodium | 55 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | suppressed |
| Olanzapine | Olanzapine | 53 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 49 | suppressed |
| Myrbetriq | Mirabegron | 46 | suppressed |
| Ozempic | Semaglutide | 45 | suppressed |
| Famotidine | Famotidine | 44 | suppressed |
| Januvia | Sitagliptin Phosphate | 44 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | suppressed |
| Spironolactone | Spironolactone | 41 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 40 | 12 |
| Carvedilol | Carvedilol | 39 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 38 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | suppressed |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Clonazepam | Clonazepam | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Allopurinol | Allopurinol | 31 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Loperamide | Loperamide Hcl | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Fentanyl | Fentanyl | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 17 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 15 |
| Sertraline Hcl | Sertraline Hcl | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 12 |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 12 |
| Insulin Aspart Flexpen | Insulin Aspart | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Cefaclor | Cefaclor | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Entacapone | Entacapone | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $220.33 · 14 records | Amgen Inc. | CAPVAXIVE, ENTRESTO, EVENITY, GARDASIL 9, JARDIANCE, LEQVIO, M-M-R II, MOUNJARO, NURTEC ODT, OTEZLA, PROLIA, PURAPLY WOUND MATRIX, REPATHA, REXULTI, VAXELIS, VAXNEUVANCE, ZAVZPRET, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error